---
title: "Refractory_relapsed Hodgkin lymphoma"
slug: "refractoryrelapsed-hodgkin-lymphoma"
date: "2023-06-01"
enableToc: false
tags:
- building
---

> [!info]
>
> ðŸŒ± ä¾†è‡ª: [[treatment of hodgkin lymphoma (HL)]]

# Refractory_relapsed Hodgkin lymphoma

## Management: Relapsed Classical Hodgkin Lymphoma
- salvage chemotherapy such as
    - [[ICE]], [[DHAP]], or [[GVD]]
    - followed by consolidative autologous stem cell transplant if responsive
- pre-SCT predictor of outcomes
    - PET-negative CR regardless of whether 1 or 2 salvage regimens is required
- Single agent [[Brentuximab]] can achieve CRs in 25â€“30% of pts & avoid multiagent chemotherapy in a subset of pts

> (JCO 1993;11:1062)
> (Blood 2012;119:1665)
> (Lancet Oncol 2015;16:284)

---

## RFs for adverse outcome post relapse
- Remission **duration <12 mos**
- B-sx
- Extranodal disease

### Rx In these pts,
- maintenance Brentuximab q3w Ã— 12 mos improves PFS

> (Blood 2001;97:616)
> (AETHERA, Lancet Oncol 2015)

---

## In pts relapsing after autologous SCT,
## 2 strategies are particularly effective:
- Brentuximab vedotin
    -  75% RR in post-ASCT setting
    -  achieves long-term remissions about 20% CR

<hr>

- PD-1 blockade w/ nivolumab or pembrolizumab
    - 65â€“70% RR
    - achieves long-term (>1 y) remissions in at least 40% of pt
    - increased risk of post-allo SCT GVHD in pts w/ prior anti-PD-1

> (Chen, Blood 2016)
> (Lancet Oncol 2016:17:1283; JCO 2016;34:2698)
